No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GNMSF GENMAB AS
- 268.130
- -3.900-1.43%
15min DelayClose Jul 22 16:00 ET
17.02BMarket Cap22.15P/E (TTM)
281.720High266.480Low1.50KVolume281.720Open272.030Pre Close414.75KTurnover0.00%Turnover Ratio27.85P/E (Static)63.47MShares417.60052wk High3.57P/B16.84BFloat Cap241.09052wk Low--Dividend TTM62.81MShs Float500.920Historical High--Div YieldTTM5.60%Amplitude241.090Historical Low276.129Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination With Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients With Previously Treated Metastatic Non-small Cell Lung Cancer (MNSCLC)
Genmab Completes Acquisition of ProfoundBio
6-K: Report of foreign private issuer (related to financial reporting)
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,959 shares as a consequence of the exercise of employee warrants. The increase is
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg